Inclusion Criteria

DISEASE CHARACTERISTICS:

- Microscopically confirmed diagnosis of pancreatic adenocarcinoma

- Unresectable disease

- No neuroendocrine tumors or cystadenocarcinoma

- Measurable or evaluable disease by RECIST criteria

- No known brain metastases

- Patients with neurological symptoms must undergo a CT scan/MRI of the brain to
exclude brain metastases

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- ANC ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

- ALT and AST ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver involvement)

- Creatinine ≤ 1.5 times ULN

- INR < 1.5 or PT/PTT normal unless patients are receiving anticoagulation treatments

- Negative pregnancy test

- Not pregnant or nursing

- Fertile patients must use effective barrier contraception before, during, and for at
least 6 months after completion of study treatment

- Able to swallow whole pills

- No patients who currently smoke

- No cardiac disease, including any of the following:

- NYHA class III-IV congestive heart failure

- Unstable angina (anginal symptoms at rest)

- New-onset angina (began within the past 3 months)

- Myocardial infarction within the past 6 months

- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

- No uncontrolled hypertension defined as systolic BP > 150 mm Hg or diastolic BP > 90
mm Hg despite optimal medical management

- No arterial thrombotic or embolic events (e.g., cerebrovascular accident, including
transient ischemic attacks) within the past 6 months

- No pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 in the past 4 weeks

- No other hemorrhage/bleeding event ≥ CTCAE grade 3 in the past 4 weeks

- No significant traumatic injury in the past 4 weeks

- No known untreated malabsorption problem (e.g., ulcerative colitis, Crohn's disease)

- No known HIV positivity or chronic hepatitis B or C

- No known or suspected allergy to sorafenib tosylate or erlotinib hydrochloride

- No active clinically serious infection > CTCAE grade 2

- No serious non-healing wound, ulcer, or bone fracture

- No evidence or history of bleeding diathesis or coagulopathy (except for
cancer-related blood clots)

- No dermatitis ≥ CTCAE grade 2 at baseline

- No patients who currently smoke

PRIOR CONCURRENT THERAPY:

- No prior treatment with antiangiogenics (e.g., bevacizumab, thalidomide, marimastat,
interferon alfa, vatalanib, vandetanib, ZD6126, sorafenib, semaxanib, sunitinib,
axitinib)

- No more than one line of prior therapy for metastatic disease

- More than 4 weeks since prior major surgery or open biopsy

- No concurrent strong CYP34A inhibitors or inducers

- Concurrent warfarin or heparin allowed with the approval of the principal
investigator